（优质课件）妊娠合并肺动脉高压的诊治演示课件.ppt

* C.H.Hsu,M.Gomberg-Maitland, C. Glassner,and J. H.Chen, “The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients,” International Journal of Clinical Practice, vol. 65, no.172, pp. 6–14, 2011. * Micrograph of the appearance of a normal (left) and an abnormal (right) pulmonary arteriole. Note the proliferation of the smooth muscle, medial thickening, and reduction in vascular diameter. Plexiform lesions (multiple small vascular channels arising within a small artery) can also be seen towards the left on the right panel (hematoxylin and eosin staining).PAH indicates pulmonary arterial hypertension. * AA indicates arachidonic acid; CCB, calcium channel blocker; ETRA, endothelin receptor antag- onist [eg, bosentan (dual), ambrisentan]; PDE5i, phosphodiesterase-5 inhibitor (eg, sildenafil). * * * Regitz-Zagrosek V, Blomstrom Lundqvist C,Borghi C, et al. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM). ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). EurHeart J. 2011;32:3147–3197.) * C.-H. Hsu, M. Gomberg-Maitland,C. Glassner, J.-H. Chen. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patientsInt J Clin Pract, August 2011, 65 (Suppl. 172), 6–14 * 21 Warnes CA. Pregnancy and pulmonary hypertension. Int J Cardiol 2004; 97: 11–3. 25 Goland S, Tsai F, Habib M, Janmohamed M, Goodwin TM, Elkayam U. Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension. Cardiology 2010; 115: 205–8. 28 Madden BP. Pulmonary hypertension and pregnancy. Int J Obstet Anesth. 2009; 18: 156–64. 41 Al-Mobeireek AF, Almutawa J, Alsatli RA. The nineteenth pregnancy in a patient with cor